These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38599494)

  • 1. GLP-1 modulated the firing activity of nigral dopaminergic neurons in both normal and parkinsonian mice.
    Liu C; Liu WH; Yang W; Chen L; Xue Y; Chen XY
    Neuropharmacology; 2024 Jul; 252():109946. PubMed ID: 38599494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropeptide apelin presented in the dopaminergic neurons modulates the neuronal excitability in the substantia nigra pars compacta.
    Liu C; Kang NW; Wang Y; Xue Y; Chen XY; Chen L
    Neuropharmacology; 2022 Nov; 219():109235. PubMed ID: 36041497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Several neuropeptides involved in parkinsonian neuroprotection modulate the firing properties of nigral dopaminergic neurons.
    Chen L; Liu C; Xue Y; Chen XY
    Neuropeptides; 2023 Jun; 99():102337. PubMed ID: 37087783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orexin-B exerts excitatory effects on nigral dopaminergic neurons and alleviates motor disorders in MPTP parkinsonian mice.
    Bian K; Liu C; Wang Y; Xue Y; Chen L
    Neurosci Lett; 2021 Nov; 765():136291. PubMed ID: 34666119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GABAergic control of rat substantia nigra dopaminergic neurons: role of globus pallidus and substantia nigra pars reticulata.
    Celada P; Paladini CA; Tepper JM
    Neuroscience; 1999 Mar; 89(3):813-25. PubMed ID: 10199615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual effects of L-DOPA on nigral dopaminergic neurons.
    Guatteo E; Yee A; McKearney J; Cucchiaroni ML; Armogida M; Berretta N; Mercuri NB; Lipski J
    Exp Neurol; 2013 Sep; 247():582-94. PubMed ID: 23481547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.
    Jalewa J; Sharma MK; Gengler S; Hölscher C
    Neuropharmacology; 2017 May; 117():238-248. PubMed ID: 28223210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orexins increase the firing activity of nigral dopaminergic neurons and participate in motor control in rats.
    Liu C; Xue Y; Liu MF; Wang Y; Liu ZR; Diao HL; Chen L
    J Neurochem; 2018 Nov; 147(3):380-394. PubMed ID: 30102759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GABAergic control of substantia nigra dopaminergic neurons.
    Tepper JM; Lee CR
    Prog Brain Res; 2007; 160():189-208. PubMed ID: 17499115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
    Kim S; Moon M; Park S
    J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
    Liu H; Jia L; Chen X; Shi L; Xie J
    Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.
    Harkavyi A; Abuirmeileh A; Lever R; Kingsbury AE; Biggs CS; Whitton PS
    J Neuroinflammation; 2008 May; 5():19. PubMed ID: 18492290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 6-OHDA induced calcium influx through N-type calcium channel alters membrane properties via PKA pathway in substantia nigra pars compacta dopaminergic neurons.
    Qu L; Wang Y; Zhang HT; Li N; Wang Q; Yang Q; Gao GD; Wang XL
    Neurosci Lett; 2014 Jul; 575():1-6. PubMed ID: 24861516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
    Porritt MJ; Batchelor PE; Howells DW
    Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptidic exenatide and herbal catalpol mediate neuroprotection via the hippocampal GLP-1 receptor/β-endorphin pathway.
    Jia Y; Gong N; Li TF; Zhu B; Wang YX
    Pharmacol Res; 2015 Dec; 102():276-85. PubMed ID: 26546042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.
    Ji C; Xue GF; Lijun C; Feng P; Li D; Li L; Li G; Hölscher C
    Brain Res; 2016 Mar; 1634():1-11. PubMed ID: 26453833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the Parkinsonian toxin MPP+ on electrophysiological properties of nigral dopaminergic neurons.
    Yee AG; Lee SM; Hunter MR; Glass M; Freestone PS; Lipski J
    Neurotoxicology; 2014 Dec; 45():1-11. PubMed ID: 25193392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-Like Peptide-1 Receptor Signaling in the Lateral Dorsal Tegmental Nucleus Regulates Energy Balance.
    Reiner DJ; Leon RM; McGrath LE; Koch-Laskowski K; Hahn JD; Kanoski SE; Mietlicki-Baase EG; Hayes MR
    Neuropsychopharmacology; 2018 Feb; 43(3):627-637. PubMed ID: 28920591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
    Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
    Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.